{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:18:24Z","timestamp":1793902704483,"version":"4.8.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ekir.2026.106511","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T23:53:44Z","timestamp":1774396424000},"page":"106511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management"],"prefix":"10.1016","volume":"11","author":[{"given":"Catherine","family":"Verhellen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Devresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Gillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Van Regemorter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Darius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Buemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106511_bib1","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival\u2014making progress when most needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transplant"},{"issue":"4S1 Suppl 1","key":"10.1016\/j.ekir.2026.106511_bib2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.kint.2017.03.015","article-title":"Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes","volume":"92","author":"Allen","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib4","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1097\/TP.0000000000003192","article-title":"Assessing the complex causes of kidney allograft loss","volume":"104","author":"Van Loon","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1503\/cmaj.051291","article-title":"Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation","volume":"173","author":"Knoll","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.ekir.2026.106511_bib6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ajt.2023.02.020","article-title":"Genetic evaluation of living kidney donor candidates: a review and recommendations for best practices","volume":"23","author":"Thomas","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40472-021-00340-3","article-title":"Evaluation of genetic kidney diseases in living donor kidney transplantation: towards precision genomic medicine in donor risk assessment","volume":"9","author":"Caliskan","year":"2022","journal-title":"Curr Transplant Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2025.151658","article-title":"Utility of genetic information for management in kidney transplantation and living donation","volume":"45","author":"Caliskan","year":"2025","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib9","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.34067\/KID.0000000000000350","article-title":"Screening of living kidney donors for genetic diseases: pro","volume":"5","author":"Caliskan","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2026.106511_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1681\/ASN.2009101093","article-title":"Recurrence of lupus nephritis after kidney transplantation","volume":"21","author":"Contreras","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib11","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/sj.ki.5002244","article-title":"Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression","volume":"71","author":"Gera","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib12","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ekir.2021.04.011","article-title":"Recurrence and outcome of anti-glomerular basement membrane glomerulonephritis after kidney transplantation","volume":"6","author":"Coche","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib13","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","article-title":"Immunoglobulin A nephropathy: recurrence after renal transplantation","volume":"10","author":"Moroni","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106511_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib15","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.2215\/CJN.00520111","article-title":"Recurrence and graft loss after kidney transplantation for Henoch-Sch\u00f6nlein purpura nephritis: a multicenter analysis","volume":"6","author":"Kanaan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ajt.2024.01.036","article-title":"Recurrence of membranous nephropathy after kidney transplantation: a multicenter retrospective cohort study","volume":"24","author":"Hullekes","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib17","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.ekir.2024.09.012","article-title":"Anti-phospholipase A2 receptor 1 antibodies and membranous nephropathy recurrence after kidney transplantation","volume":"9","author":"Cremoni","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib18","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.ajkd.2020.01.009","article-title":"Association of HLA typing and alloimmunity with posttransplantation membranous nephropathy: a multicenter case series","volume":"76","author":"Batal","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106511_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.kint.2020.08.007","article-title":"HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients","volume":"99","author":"Berchtold","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-6143.2011.03818.x","article-title":"Increased risk of recurrence of membranous nephropathy after related donor kidney transplantation","volume":"12","author":"Andr\u00e9sd\u00f3ttir","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib23","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib24","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/TP.0000000000000630","article-title":"Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy","volume":"99","author":"Quintana","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ctr.12711","article-title":"Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation","volume":"30","author":"Gupta","year":"2016","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2026.106511_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/jcm10040607","article-title":"Advances in membranous nephropathy","volume":"10","author":"Ronco","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106511_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib29","series-title":"Guidelines for Living Donor Kidney Transplantation","year":"2018"},{"key":"10.1016\/j.ekir.2026.106511_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2025.14024","article-title":"Evaluating risk in kidney living donors","volume":"38","author":"Ortiz","year":"2025","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2026.106511_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2369-14-47","article-title":"A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation","volume":"14","author":"Maas","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2023.10.017","article-title":"Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements","volume":"105","author":"Raina","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gfk005","article-title":"Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients","volume":"21","author":"Pardon","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ndt\/gfae108","article-title":"Prophylactic treatment of FSGS recurrence in patients who relapsed on a previous kidney graft","volume":"40","author":"Uro-Coste","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib36","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.3390\/jcm11123292","article-title":"Biomarkers in primary focal segmental glomerulosclerosis in optimal diagnostic-therapeutic strategy","volume":"11","author":"Musia\u0142a","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2026.106511_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa2314471","article-title":"= Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib38","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.kint.2023.11.022","article-title":"A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence","volume":"105","author":"Shirai","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.kint.2024.07.022","article-title":"Pre-transplant anti-nephrin antibodies are specific predictors of recurrent diffuse podocytopathy in the kidney allograft","volume":"106","author":"Batal","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.kint.2025.04.015","article-title":"Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis","volume":"108","author":"Habbig","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib41","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.kint.2025.01.018","article-title":"A kidney organoid-based readout to assess disease activity in primary and recurrent focal segmental glomerulosclerosis","volume":"107","author":"Gupta","year":"2025","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2026.106511_bib42","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5500\/wjt.v11.i7.303","article-title":"Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: a systematic review and meta-analysis","volume":"11","author":"Boonpheng","year":"2021","journal-title":"World J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MNH.0000000000000946","article-title":"Current approaches to overcome recurrent focal segmental glomerulosclerosis after kidney transplantation","volume":"33","author":"Ahmad","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ekir.2026.106511_bib45","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ajt.2024.06.010","article-title":"Rescue with obinutuzumab and daratumumab as combined B cell\/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence","volume":"24","author":"Randone","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib46","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ekir.2026.106511_bib47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ndt\/gfh173","article-title":"Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy","volume":"19","author":"Ghiggeri","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib48","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11560-021-00561-8","article-title":"KDIGO guideline on the evaluation and management of candidates for kidney transplantation: commented German translation of the summary","volume":"17","author":"Morath","year":"2022","journal-title":"Nephrologe"},{"key":"10.1016\/j.ekir.2026.106511_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40472-025-00466-8","article-title":"Complement-mediated kidney disease and living donor transplantation: tailoring approaches to improve outcomes","volume":"12","author":"Memon","year":"2025","journal-title":"Curr Transplant Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib53","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ekir.2022.02.021","article-title":"The rational use of complement inhibitors in kidney diseases","volume":"7","author":"Fakhouri","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib54","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.mayocp.2018.07.008","article-title":"Diagnostic utility of complement serology for atypical hemolytic uremic syndrome","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2026.106511_bib55","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib56","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106511_bib57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.kint.2019.04.011","article-title":"Defects in complement and \u201csecondary\u201d hemolytic uremic syndrome","volume":"96","author":"Timmermans","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib58","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ekir.2021.02.012","article-title":"C5 inhibition in secondary thrombotic microangiopathies: a yet unresolved question","volume":"6","author":"Werion","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2026.106511_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","article-title":"UCLouvain TMA\/HUS network and KU Leuven TMA\/HUS network. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies","volume":"18","author":"Werion","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib61","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/ndt\/gfaf091","article-title":"Complement activation in secondary thrombotic microangiopathies","volume":"40","author":"Morelle","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib63","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib64","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib65","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib66","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ekir.2023.12.003","article-title":"Monogenic kidney diseases in kidney transplantation","volume":"9","author":"Gillion","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib67","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib68","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258319","article-title":"Thrombotic microangiopathy after kidney transplantation: analysis of the Brazilian atypical hemolytic uremic syndrome cohort","volume":"16","author":"Nga","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2026.106511_bib70","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","article-title":"Haemolytic uraemic syndrome","volume":"400","author":"Michael","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106511_bib71","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s40620-021-01045-7","article-title":"Kidney transplant in patients with atypical hemolytic uremic syndrome in the anti-C5 era: single-center experience with tailored eculizumab","volume":"34","author":"Ardissino","year":"2021","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib72","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106511_bib73","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106511_bib74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ndt\/gfaf166","article-title":"Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS","volume":"41","author":"Orozco-Leal","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5414\/CN110516","article-title":"Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data","volume":"97","author":"Tomazos","year":"2022","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant"},{"issue":"8S Suppl 1","key":"10.1016\/j.ekir.2026.106511_bib78","first-page":"S1","article-title":"KDIGO clinical practice guideline on the evaluation and care of living kidney donors","volume":"101","author":"Lentine","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib79","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nrneph.2012.213","article-title":"Pathogenesis of the C3 glomerulopathies and reclassification of MPGN","volume":"8","author":"Bomback","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"4S1 Suppl 1","key":"10.1016\/j.ekir.2026.106511_bib80","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib82","first-page":"10","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study","volume":"35","author":"Nester","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib83","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib84","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106511_bib85","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf134","article-title":"Kidney transplant in patients with C3 glomerulopathy","volume":"18","author":"Attieh","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106511_bib86","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ekir.2024.09.030","article-title":"Efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent complement 3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis","volume":"10","author":"Bomback","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib87","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib88","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.ekir.2026.106511_bib89","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.ekir.2024.11.300","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-month results from the phase 3 APPEAR-C3G study","volume":"10","author":"Nester","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100823","article-title":"Factor B inhibition with iptacopan in recurrent C3 glomerulopathy following kidney transplant: a report of two cases","volume":"6","author":"Escudero-Saiz","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106511_bib91","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib92","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ajt.13042","article-title":"Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting","volume":"15","author":"Barbour","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib93","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrneph.2012.113","article-title":"An update on primary hyperoxaluria","volume":"8","author":"Hoppe","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib95","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","article-title":"Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives","volume":"5","author":"Devresse","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106511_bib96","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","article-title":"The primary hyperoxalurias","volume":"75","author":"Hoppe","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib97","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12882-021-02546-0","article-title":"Primary hyperoxaluria diagnosed after kidney transplantation: a case report and literature review","volume":"22","author":"Cai","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2026.106511_bib98","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1111\/ajt.15829","article-title":"Primary hyperoxaluria type 2 successfully treated with combined liver-kidney transplantation after failure of isolated kidney transplantation","volume":"20","author":"Del Bello","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib99","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00467-021-05043-6","article-title":"Transplantation outcomes in patients with primary hyperoxaluria: a systematic review","volume":"36","author":"Metry","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"6S1","key":"10.1016\/j.ekir.2026.106511_bib100","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2025.02.602","article-title":"US renal data system 2024 annual data report: epidemiology of kidney disease in the United States","volume":"85","author":"Johansen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106511_bib101","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1097\/TP.0000000000003597","article-title":"Liver transplantation in primary hyperoxaluria type 1: we have to find an alternative","volume":"105","author":"Devresse","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib102","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.ajkd.2025.01.016","article-title":"Efficacy and safety of lumasiran for advanced primary hyperoxaluria type 1: 24-month follow-up of the phase 3 ILLUMINATE-C trial","volume":"86","author":"Sellier-Leclerc","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106511_bib103","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106511_bib104","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJMc2312941","article-title":"Lumasiran, isolated kidney transplantation, and continued vigilance","volume":"390","author":"Bacchetta","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106511_bib105","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/TP.0000000000003170","article-title":"Kidney transplantation in systemic amyloidosis","volume":"104","author":"Angel-Korman","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib106","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/TP.0000000000005191","article-title":"Kidney transplant outcomes in amyloidosis: US national database study","volume":"109","author":"Yamauchi","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106511_bib107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106511_bib108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ekir.2026.106511_bib109","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.kint.2018.11.003","article-title":"Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice","volume":"95","author":"Nuvolone","year":"2019","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:24:50Z","timestamp":1780478690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468024926027439"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106511","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106511"}}